Science Letter
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Science Letter
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acute Bacterial Sinusitis
Single-dose antibiotic Zmax receives FDA approval
July 12th, 2005
Pfizer Inc said that the U.S. Food and Drug Administration (FDA) has approved Zmax (azithromycin extended release) for oral suspension, a one-dose-only treatment for mild-to-moderate acute bacterial sinusitis (ABS) and community-acquired pneumonia (CAP) in adults. Using microsphere technology, ZMax delivers a complete course of therapy in a single two-gram dose. In the first 24 hours after a dose of Zmax, the amount of drug that gets into the tissue is three times higher than a standard dose of immediate-release azithromycin. Immediate-release azithromycin has been available in the United States since 1992 under the trade name Zithromax. This "front loading" of Zmax...
Source: Science Letter (2005-07-12)
|
